Answers are grounded in this paper and cite their sources.
Monoclonal antibodies were used to probe the cell surface of organ-selected metastatic variant cells. Previously we defined a liver metastasis-associated antigen (LMAA) by means of the reaction of a monoclonal antibody with a liver metastasis selected tumour variant cell line, MDCC-AL2. The monoclonal anti-LMAA antibodies specifically inhibit liver metastasis of AL2. There is a correlated, clonal variation in LMAA expression and liver metastasis in both the AL2 cell line and an overy-selected metastatic variant MDCC-AL3. The variation in liver metaatatic ability is thought to represent clonal progression of the tumour cell lines. The LMAA probably represents only one of the ways in which a tumour cell may give rise to a live metastasis. Two hypotheses are discussed utilizing the LMAA in a functional role in the specific trapping of metastatic tumour cells in the liver or the successful colonization of the liver by metastatic tumour cells.
No takes yet. Share an insight, caveat, or question.
Shearman et al. (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: